Study of Batoclimab in Myasthenia Gravis (MG)
- Study HIC#:2000033964
- Last Updated:11/20/2023
If you are over the age of 18 years old, have a diagnosis of generalized Myasthenia Gravis, and take a stable dose of MG medication, you may be eligible to participate in a trial testing the safety and effectiveness of a new medication called batoclimab. The study will determine if batoclimab will help improve the symptoms of MG. Compensation for your time is available.
- Age18 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Erika Renkl
- Phone Number: 1-475-254-9169
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
The purpose of this 3-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo.
Eligibility Criteria
To pre-qualify for this study, you must:
• Be 18 years of age or older
• Have been diagnosed with gMG
• Have been treated or are currently being treated with medication for Gmg
- Additional criteria will apply.
